Boundless Bio Future Growth
Future criteria checks 0/6
Boundless Bio's earnings are forecast to decline at 22.8% per annum while its annual revenue is expected to grow at 77.8% per year. EPS is expected to grow by 15.3% per annum.
Key information
-22.8%
Earnings growth rate
15.3%
EPS growth rate
| Biotechs earnings growth | 30.0% |
| Revenue growth rate | 77.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -115 | -91 | -94 | 3 |
| 12/31/2025 | N/A | -89 | -74 | -86 | 3 |
| 12/31/2024 | N/A | -66 | -58 | -65 | 3 |
| 6/30/2024 | N/A | -58 | -58 | -56 | N/A |
| 3/31/2024 | N/A | -53 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -49 | -47 | -47 | N/A |
| 9/30/2023 | N/A | -49 | -46 | -45 | N/A |
| 6/30/2023 | N/A | -49 | -44 | -44 | N/A |
| 3/31/2023 | N/A | -47 | -43 | -42 | N/A |
| 12/31/2022 | N/A | -46 | -41 | -40 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOLD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BOLD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BOLD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BOLD is forecast to have no revenue next year.
High Growth Revenue: BOLD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BOLD's Return on Equity is forecast to be high in 3 years time